【摘要】：研究背景及目的:大腸癌是最常見的惡性腫瘤之一,近20年來,在我國發(fā)病率呈迅速增長的趨勢(shì),其死亡率已上升至惡性腫瘤的第三位。2型糖尿病的發(fā)病率,在世界范圍內(nèi)也在不斷增加,預(yù)計(jì)2030年將上升至4.4%,約4.39億人次。流行病學(xué)和臨床研究均顯示2型糖尿病和大腸癌之間有著共同的危險(xiǎn)因素,且相互促進(jìn)。2型糖尿病人群中,大腸癌的發(fā)病及死亡風(fēng)險(xiǎn)增加,且預(yù)后差�，F(xiàn)有研究顯示,2型糖尿病時(shí)高胰島素、活性氧增加等與大腸癌發(fā)生發(fā)展有關(guān),同時(shí),2型糖尿病時(shí)去甲腎上腺素水平增高也是大腸癌發(fā)生風(fēng)險(xiǎn)增高的重要誘因。精氨酸特異性單ADP核糖基轉(zhuǎn)移酶1(ART1)是一種重要的單ADP核糖基轉(zhuǎn)移酶,被認(rèn)為與多種細(xì)胞生物學(xué)行為有著密切的關(guān)系。課題組前期研究顯示,ART1的表達(dá)變化,可以影響大腸癌細(xì)胞的增殖、侵襲轉(zhuǎn)移、分化、微血管形成、自噬及凋亡,參與大腸癌的發(fā)生及發(fā)展;ART1與胰島素信號(hào)通路肝糖原調(diào)節(jié)的負(fù)性調(diào)節(jié)子磷酸化GSK-3β蛋白表達(dá)有關(guān),提示ART1可能在糖代謝性疾病中發(fā)揮作用。但ART1對(duì)2型糖尿病高NE狀態(tài)下大腸癌生長影響及機(jī)制研究,尚未見相關(guān)報(bào)道。本課題旨在前期研究的基礎(chǔ)上,從三方面入手,首先探討2型糖尿病合并大腸癌患者癌組織ART1的表達(dá)變化,其次建立balb/C2型糖尿病小鼠模型,采用課題組前期制備的不同ART1表達(dá)水平的CT26細(xì)胞,建立小鼠移植瘤模型,此外,以去甲腎上腺素誘導(dǎo)不同ART1表達(dá)水平的CT26細(xì)胞,從在體及離體兩方面,探討ART1對(duì)2型糖尿病高NE狀態(tài)大腸癌生長的影響及其可能的分子機(jī)制。為ART1作為治療2型糖尿病合并大腸癌的候選靶點(diǎn)提供實(shí)驗(yàn)依據(jù)。方法:本研究分為三部分進(jìn)行。1.2型糖尿病合并大腸癌癌組織ART1表達(dá)變化采用免疫組化方法,檢測大腸癌組織ART1表達(dá)。比較大腸癌合并2型糖尿病(CRCD)組(n=37例)與大腸癌未合并糖尿病(CRCO)組(n=23例)ART1表達(dá)強(qiáng)度的變化,并分析ART1表達(dá)強(qiáng)度與糖尿病的關(guān)系。2.ART1對(duì)2型糖尿病高NE狀態(tài)小鼠大腸癌生長的影響(1)離體實(shí)驗(yàn)選用四組CT26細(xì)胞:ART1高表達(dá)組(GFP-ART1組),空載體組(GFP-Vector組),ART1沉默組(GFP-Sh ART1組),未轉(zhuǎn)染組(Un-transfection組)。1)CCK8法,評(píng)估ART1對(duì)不同NE濃度誘導(dǎo)CT26細(xì)胞增殖活性的影響及ART1對(duì)NE不同時(shí)間誘導(dǎo)CT26細(xì)胞增殖活性影響。2)流式細(xì)胞術(shù)評(píng)估ART1對(duì)NE誘導(dǎo)各組CT26細(xì)胞周期的影響。(2)在體實(shí)驗(yàn)1)2型糖尿病小鼠模型的建立采用高脂飼料喂養(yǎng)及腹腔注射1%鏈脲菌素(STZ)的方法建立2型糖尿病Balb/c小鼠模型。對(duì)照組Balb/c小鼠腹腔注射等體積生理鹽水。尾靜脈采血檢測小鼠血糖,以確定模型的建立,同時(shí)檢測去甲腎上腺素及胰島素水平。2)不同ART1水平2型糖尿病大腸癌移植瘤體積及重量和小鼠荷瘤生存時(shí)間檢測以糖尿病Balb/c小鼠為實(shí)驗(yàn)組,非糖尿病Balb/c小鼠為對(duì)照組,小鼠右側(cè)腋窩皮下分別接種四組CT26細(xì)胞,即ART1高表達(dá)CT26細(xì)胞(GFP-ART1組)、ART1沉默CT26細(xì)胞(GFP-sh ART1組)、未轉(zhuǎn)染CT26細(xì)胞(Un-transfection組)和空載體轉(zhuǎn)染CT26細(xì)胞(GFP-Vector組),建立Balb/c小鼠大腸癌移植瘤模型。觀測各組小鼠體重變化、移植瘤體積及重量;觀測各組小鼠荷瘤生存時(shí)間。3)ART1高表達(dá)對(duì)2型糖尿病小鼠不同NE水平大腸癌移植瘤生長的影響采用左腎交感神經(jīng)離斷術(shù),建立糖尿病血循環(huán)低NE水平Balb/c小鼠模型。尾靜脈采血檢測小鼠去甲腎上腺素(NE)以確定模型的建立,同時(shí)檢測血糖及胰島素水平。在小鼠右側(cè)腋窩皮下接種ART1高表達(dá)CT26細(xì)胞。以手術(shù)組(LRD組)為實(shí)驗(yàn)組,未手術(shù)組(GFP-ART1組)和假手術(shù)組(LSO組)為對(duì)照組,觀測各組小鼠移植瘤體積及重量。3、ART1對(duì)2型糖尿病高NE狀態(tài)小鼠大腸癌生長影響的機(jī)制(1)離體實(shí)驗(yàn)ART1對(duì)高NE誘導(dǎo)的小鼠大腸癌CT26細(xì)胞p-AKT、AKT、m TOR、STAT3、Cyclin D1及c-myc蛋白表達(dá)影響選用四組CT26細(xì)胞:ART1高表達(dá)組(GFP-ART1組),空載體組(GFP-Vector組),ART1沉默組(GFP-Sh ART1組),未轉(zhuǎn)染組(Un-transfection組)。以終濃度為1μmmol/l NE誘導(dǎo)各組CT26細(xì)胞。采用western blot檢測各組細(xì)胞ART1、p-AKT、m TOR、STAT3、Cyclin D1、c-myc蛋白表達(dá)變化。(2)在體實(shí)驗(yàn)1)2型糖尿病高NE狀態(tài)小鼠大腸癌移植瘤ART1、P-AKT、m TOR及STAT3表達(dá)變化采用Western blot方法,以非糖尿病小鼠移植瘤為對(duì)照組,檢測糖尿病小鼠移植瘤組織ART1、p-AKT、AKT、m TOR、STAT3的蛋白表達(dá)變2)ART1高表達(dá)對(duì)2型糖尿病不同NE水平小鼠大腸癌移植瘤組織p-AKT、AKT、m TOR、STAT3蛋白表達(dá)影響采用western blot方法,以未手術(shù)組(GFP-ART1組)和假手術(shù)組(LSO組)為對(duì)照組,檢測手術(shù)組(LRD組)移植瘤組織ART1、p-AKT、AKT、m TOR、STAT3蛋白表達(dá)變化。結(jié)果:1、2型糖尿病合并大腸癌癌組織ART1表達(dá)變化(1)免疫組化檢測人大腸癌組織中ART1的表達(dá)ART1著色部位主要位于腫瘤細(xì)胞胞質(zhì)及胞膜。CRCD組ART1的表達(dá)強(qiáng)度明顯高于CRCO組,且有統(tǒng)計(jì)學(xué)差異(p0.05)。即使對(duì)年齡、性別、腫瘤部位、浸潤深度、等因素進(jìn)行較正后,2型糖尿病仍是ART1表達(dá)強(qiáng)度的獨(dú)立相關(guān)因素。2、ART1對(duì)2型糖尿病高NE狀態(tài)小鼠大腸癌生長的影響(1)離體實(shí)驗(yàn)1)ART1對(duì)不同NE濃度誘導(dǎo)CT26細(xì)胞增殖活性影響CCK8法檢測各組細(xì)胞的增殖活性。結(jié)果顯示,隨著NE濃度的增加,GFP-ART1、Un-transfection、GFP-Vector組細(xì)胞的增殖活性增加,但GFP-Sh ART1組細(xì)胞增殖活性無明顯變化。GFP-ART1組,相較其余三組,細(xì)胞增殖活性最高,GFP-Sh ART1組相較其余三組增殖活性最低(p0.05),Un-transfection、GFP-Vector組細(xì)胞間則無統(tǒng)計(jì)學(xué)差異(P0.05)。2)ART1對(duì)NE不同時(shí)間誘導(dǎo)CT26細(xì)胞增殖活性影響CCK8結(jié)果顯示,以終濃度為1μmmol/l NE分別誘導(dǎo)四組CT26細(xì)胞,在各誘導(dǎo)處理時(shí)間,GFP-ART1組,相較其余三組,細(xì)胞增殖活性最高,GFP-Sh ART1組相較其余三組增殖活性最低(p0.05)。且隨誘導(dǎo)時(shí)間的延長,GFP-ART1,Un-transfection和GFP-Vector組細(xì)胞增殖活性增加(p0.05),但GFP-Sh ART1組細(xì)胞增殖活性似乎沒有明顯變化(P0.05)。Un-transfection、GFP-Vector組細(xì)胞間則無統(tǒng)計(jì)學(xué)差異(P0.05)。3)ART1對(duì)NE誘導(dǎo)CT26細(xì)胞周期影響NE誘導(dǎo)CT26細(xì)胞后,未經(jīng)NE誘導(dǎo)的各對(duì)照組細(xì)胞:(1)ART1高表達(dá)組,未轉(zhuǎn)染組及空載體組可見G1期比例明顯減少,S期比例明顯增加,細(xì)胞增殖指數(shù)PI明顯增加(p0.05);(2)GFP-sh ART1組,即ART1沉默組,各時(shí)期細(xì)胞分布及PI無明顯改變(P0.05)。無論各組CT26細(xì)胞有無NE誘導(dǎo),GFP-ART1組,G1期比例最少,S期比例最多,PI增加(p0.05)。Un-transfection、GFP-Vector組細(xì)胞間則無統(tǒng)計(jì)學(xué)差異(P0.05)。(2)在體實(shí)驗(yàn)1)2型糖尿病小鼠模型的建立高脂飲食飼養(yǎng)及腹腔注射1%STZ后,小鼠體型肥胖,體重明顯重于對(duì)照組(P0.05);小鼠血糖、胰島素水平明顯高于對(duì)照組(P0.01),小鼠NE也明顯高于對(duì)照組(P0.01),表明糖尿病動(dòng)物模型建立成功。2)不同ART1水平2型糖尿病大腸癌移植瘤體積及重量和小鼠荷瘤生存時(shí)間變化相同ART1表達(dá)水平CT26細(xì)胞接種后,與CRCO組比較,CRCD組小鼠移植瘤體積更大,重量更重,荷瘤生存時(shí)間更短,差異均具有統(tǒng)計(jì)學(xué)意義(p0.05)。CRCD組和CRCO組中,接種GFP-ART1 CT26細(xì)胞組移植瘤體積均為最大,重量最重,荷瘤生存時(shí)間最短,差異均具有統(tǒng)計(jì)學(xué)意義(p0.05);接種GFP-sh ART1 CT26細(xì)胞,移植瘤體積均最小,重量最輕,荷瘤生存時(shí)間最長,差異均具有統(tǒng)計(jì)學(xué)意義(P0.05);未轉(zhuǎn)染組與空載組則均無明顯差異(P0.05)。3)ART1高表達(dá)對(duì)2型糖尿病小鼠不同NE水平大腸癌移植瘤生長的影響與未手術(shù)組(GFP-ART1組)和假手術(shù)組(LSO組)比較,LRD組小鼠,NE水平,胰島素水平及血糖水平明顯下降(P0.01);移植瘤重量最輕,體積最小,差異具有統(tǒng)計(jì)學(xué)意義(P0.01)。GFP-ART1組和LSO組間則無統(tǒng)計(jì)學(xué)意義差異(P0.05)。3、ART1對(duì)2型糖尿病高NE狀態(tài)小鼠大腸癌生長影響的機(jī)制(1)離體實(shí)驗(yàn)ART1對(duì)高NE誘導(dǎo)的小鼠大腸癌CT26細(xì)胞p-AKT、m TOR、STAT3、Cyclin D1及c-myc蛋白表達(dá)影響1)GFP-ART1組與un-transfection組相比較,ART1、p-AKT、m TOR、STAT3、Cyclin D1、c-myc蛋白表達(dá)明顯增加(p0.05)。2)GFP-sh ART1組與GFP-Vector組相比較,ART1、p-AKT、m TOR、STAT3、Cyclin D1、c-myc蛋白表達(dá)明顯減少(p0.05)。3)un-transfection組與GFP-Vector組,各蛋白表達(dá)無明顯差異(P0.05)。(2)在體實(shí)驗(yàn)1)2型糖尿病高NE狀態(tài)小鼠移植瘤ART1、P-AKT、m TOR及STAT3表達(dá)變化Western blot顯示:與CRCO組比較,CRCD移植瘤組織,ART1、m TOR、STAT3、P-AKT蛋白表達(dá)明顯增加,(p0.01),AKT的表達(dá),兩組間無明顯差異(P0.05)。2)ART1高表達(dá)對(duì)2型糖尿病不同NE水平小鼠大腸癌移植瘤組織p-AKT、AKT、m TOR、STAT3蛋白表達(dá)影響Western blot顯示:未手術(shù)組(GFP-ART1組)、假手術(shù)組(LSO組)、LRD組,瘤體組織,ART1、AKT蛋白表達(dá)三組間無明顯差異(P0.05),GFP-ART1組及LSO組P-AKT,m TOR、STAT3蛋白表達(dá)明顯高于LSD組及GFP-ART1組(p0.05)。結(jié)論:1、大腸癌合并2型糖尿病時(shí),癌組織ART1表達(dá)明顯增強(qiáng),且伴淋巴轉(zhuǎn)移組表達(dá)強(qiáng)度高于未轉(zhuǎn)移組。ART1表達(dá)強(qiáng)度與性別、分化程度及腫瘤部位無關(guān);但對(duì)年齡、性別、腫瘤部位、侵潤深度、等因素進(jìn)行較正后,糖尿病仍是ART1表達(dá)強(qiáng)度的獨(dú)立相關(guān)因素。提示ART1可能在2型糖尿病合并大腸癌時(shí),對(duì)腫瘤發(fā)生發(fā)展發(fā)揮了一定作用。2、2型糖尿病小鼠大腸癌移植瘤生長更快,體積更大,重量更重,生存時(shí)間更短,且在ART1高表達(dá)時(shí),上述現(xiàn)象更明顯;沉默ART1對(duì)NE誘導(dǎo)的大腸癌CT26細(xì)胞增殖活性具有抑制作用,細(xì)胞主要阻滯在G1期。提示ART1對(duì)2型糖尿病小鼠大腸癌移植瘤生長具有促進(jìn)作用。3、糖尿病高NE狀態(tài)下,ART1可通過對(duì)AKT調(diào)節(jié),進(jìn)而影響AKT/m TOR/STAT3信號(hào)通路,干預(yù)其下游基因cyclin D1、c-myc表達(dá),影響大腸癌細(xì)胞的增殖。ART1有望成為糖尿病伴高NE水平時(shí)合并大腸癌治療候選靶點(diǎn)。
[Abstract]:Background and purpose: colorectal cancer is one of the most common malignant tumors. In the past 20 years, the incidence of the disease is increasing rapidly in China. The incidence of the third.2 type diabetes which has risen to malignant tumor is increasing in the world. It is expected to rise to 4.4%, about 439 million people in 2030. The bed studies have shown that there is a common risk factor between type 2 diabetes and colorectal cancer and that among people with type.2 diabetes, the risk of colorectal cancer and death is increased and the prognosis is poor. The present study shows that high insulin and active oxygen increase in type 2 diabetes are associated with the development of colorectal cancer, and the normethylene kidney in type 2 diabetes mellitus The increase of the level of the gland is also an important cause of the increased risk of colorectal cancer. Arginine specific single ADP ribonucleotransferase 1 (ART1) is an important single ADP ribonucleotransferase, which is considered to be closely related to a variety of cellular biological behavior. Proliferation, invasion, metastasis, differentiation, microvascular formation, autophagy and apoptosis are involved in the development and development of colorectal cancer; ART1 is associated with the expression of GSK-3 beta protein expression of the negative regulator of liver glycogen regulated by insulin signaling pathway, suggesting that ART1 may play a role in glycometabolic diseases. But ART1 is the growth of colorectal cancer in the high NE state of type 2 diabetes. The study of influence and mechanism has not yet been reported. On the basis of early study, this topic begins with three aspects, first to discuss the changes in the expression of ART1 in the cancer tissue of patients with type 2 diabetes and colorectal cancer, secondly to establish a model of balb/C2 type diabetes in mice, and to establish a small CT26 cell with different ART1 expression levels prepared by the project group. In addition, CT26 cells with different ART1 expression levels were induced by norepinephrine, and the effect of ART1 on the growth of high NE colorectal cancer in type 2 diabetes mellitus and its possible molecular mechanism were investigated from two aspects in vivo and in vitro. This provides an experimental basis for the treatment of ART1 as a candidate target for the treatment of type 2 diabetes with colorectal cancer. The study was divided into three parts, which were divided into three parts. The expression of ART1 expression in the tissues of type.1.2 diabetes and colorectal cancer by immunohistochemical method was used to detect the expression of ART1 in colorectal cancer tissue. The changes in the expression of ART1 in the group of large intestine cancer with type 2 diabetes mellitus (CRCD) and colorectal cancer (CRCO) group (n=23 cases) were compared, and the expression intensity and sugar of ART1 were analyzed. The effect of.2.ART1 on the growth of colorectal cancer in type 2 diabetic mice with high NE status (1) in vitro, four groups of CT26 cells were selected: ART1 high expression group (GFP-ART1 group), GFP-Vector group (group GFP-Vector), ART1 silence group (GFP-Sh ART1 group), non transfection group (Un-transfection group).1) CCK8 method Effect of activity and effect of ART1 on the proliferation of CT26 cells induced by NE at different time.2) flow cytometry was used to evaluate the effect of ART1 on CT26 cell cycle induced by NE. (2) in body experiment 1) the establishment of a model of type 2 diabetic mice by feeding high fat feed and intraperitoneal injection of 1% streptozotocin (STZ) to establish a model of type 2 diabetic Balb/c mice The Balb/c mice in the control group were intraperitoneally injected with equal volume of normal saline. The blood glucose was detected in the tail vein to determine the model, at the same time, the volume and weight of the transplanted tumor and the tumor survival time of the mice with different ART1 levels of type 2 diabetic colorectal cancer were detected at the same level of norepinephrine and insulin level.2). The experimental group of diabetic Balb/c mice was tested. Non diabetic Balb/c mice as control group, four groups of CT26 cells were inoculated subcutaneously in the right armpit of mice, namely, ART1 high expression CT26 cells (group GFP-ART1), ART1 silent CT26 cells (GFP-sh ART1 group), non transfected CT26 cells (Un-transfection group) and empty carrier transfected CT26 cells (Group). The mice model of colorectal carcinoma transplantation tumor was established. The body weight change, the volume and weight of the transplanted tumor, the tumor bearing time of the mice in each group.3) ART1 high expression on the growth of different NE levels of colorectal cancer in type 2 diabetic mice, the left renal sympathetic disconnection was used to establish a Balb/c mouse model with low blood circulation NE level in diabetic mice. Adenin (NE) was used to determine the establishment of the model, and at the same time the blood glucose and insulin levels were detected. ART1 high expression CT26 cells were subcutaneously inoculated in the right armpit of mice. The operation group (group LRD) was the experimental group, the non operation group (group GFP-ART1) and the sham operation group (group LSO) were used as the control group. The volume and weight of the transplanted tumor in each group were observed and.3, and ART1 was highly NE state of type 2 diabetes. The mechanism of the effect of the growth of colorectal cancer in mice (1) in vitro experiment, the effects of ART1 on the expression of p-AKT, AKT, m TOR, STAT3, Cyclin D1 and c-myc protein in CT26 cells induced by high NE in mice were selected as the expression of CT26 cells: the high expression group, the empty body group, the silent group and the untransfected group. CT26 cells were induced with final concentration of 1 mmol/l NE. Western blot was used to detect ART1, p-AKT, m TOR, STAT3, Cyclin D1, and protein expression changes. (2) in body experiment 1) colorectal cancer transplantation tumor of type 2 diabetic mice For the control group, the expression of ART1, p-AKT, AKT, m TOR, STAT3 was 2) in the transplanted tumor tissues of diabetic mice. The high expression of ART1 on the colorectal cancer transplanted tumor tissues of the mice with type 2 diabetes, p-AKT, AKT, m TOR, was used as the control group, and the control group and the sham operation group as the control group. The changes of the expression of ART1, p-AKT, AKT, m TOR, STAT3 protein in the transplanted tumor tissue of the operation group (group LRD). Results: the expression of ART1 expression in the tissues of 1,2 type diabetes combined with colorectal cancer (1) the expression of ART1 stained part of ART1 in human colorectal cancer tissue was mainly located in the cytoplasm and the cell membrane.CRCD group. And there was a statistical difference (P0.05). Even for age, sex, tumor site, depth of infiltration, and other factors, type 2 diabetes was still an independent factor in ART1 expression.2, ART1 had an effect on the growth of colorectal cancer in the high NE state of type 2 diabetes in mice (1) 1 in vitro.) ART1 had an effect on the proliferation of CT26 cells induced by different NE concentrations. The results showed that the proliferation activity of GFP-ART1, Un-transfection, GFP-Vector group increased with the increase of NE concentration, but the proliferation activity of GFP-Sh ART1 group had no obvious changes in.GFP-ART1 group, compared with the other three groups, the cell proliferation activity was the highest, GFP-Sh ART1 group compared with the other three groups, the proliferation activity was the lowest (P). 0.05), there was no statistical difference between Un-transfection and GFP-Vector groups (P0.05).2) ART1 on the proliferation activity of CT26 cells induced by NE at different times, and CCK8 results showed that four groups of CT26 cells were induced at the final concentration of 1 u mmol/l NE respectively. The cell proliferation activity was the highest in the induction time, GFP-ART1 group and the other three groups. The proliferation activity of the other three groups was the lowest (P0.05). And with the prolongation of the induction time, the proliferation activity of GFP-ART1, Un-transfection and GFP-Vector increased (P0.05), but the proliferation activity of GFP-Sh ART1 group did not seem to be significantly changed (P0.05).Un-transfection, and there was no statistical difference between the GFP-Vector groups (P0.05).3) Cell cycle influence NE induced CT26 cells, without NE induced cells: (1) ART1 high expression group, untransfected group and empty body group can obviously decrease the proportion of G1 stage, the proportion of S phase obviously increase, cell proliferation index PI obviously increase (P0.05); (2) GFP-sh ART1 group, that is, ART1 silencing group, cell distribution and PI have no obvious changes at all times. No matter whether the CT26 cells were induced by NE, the proportion of GFP-ART1, the G1 stage was the least, the S stage was the most, PI increased (P0.05).Un-transfection, and there was no statistical difference between the GFP-Vector group (P0.05). (2) in the body experiment 1) the establishment of high fat diet and celiac injection 1%STZ in the model of type 2 diabetes mice was obese and weight was significantly heavier than that in the model of type 2 diabetic mice. Control group (P0.05), mice blood glucose, insulin level was significantly higher than the control group (P0.01), mice NE was also significantly higher than the control group (P0.01), indicating the establishment of diabetic animal model successful.2) different ART1 Level 2 diabetes large intestine cancer transplantation tumor volume and weight and mice bearing tumor survival time changes the same ART1 expression level CT26 cell inoculation, and CRC Compared with group O, the tumor size of the mice in group CRCD was larger, weight was heavier, and the survival time of the tumor was shorter. The difference was statistically significant (P0.05) in group.CRCD and CRCO, the size of the transplanted tumor in the GFP-ART1 CT26 cell group was the largest, the weight was the heaviest, the survival time of the tumor bearing was the shortest, the difference was statistically significant (P0.05); GFP-sh ART1 CT26 was inoculated. Cells, the size of the transplanted tumor was the smallest, the weight was the lightest, the life time of the tumor bearing was the longest, and the difference was statistically significant (P0.05), and there was no significant difference between the untransfected group and the empty group (P0.05).3). The effect of high expression of ART1 on the growth of colorectal cancer in different NE levels of type 2 diabetic mice was compared with that of the unoperated group (group GFP-ART1) and the sham operation group (group LSO). Compared with group LRD, NE level, insulin level and blood glucose level decreased significantly (P0.01), the weight of the transplanted tumor was the lightest, the volume was the smallest, the difference was statistically significant (P0.01), there was no statistical difference between.GFP-ART1 and LSO groups (P0.05).3, ART1 on the growth of colorectal cancer in mice with high NE status of type 2 diabetes mellitus (1) ART1 on high N E induced mouse colorectal cancer CT26 cells p-AKT, m TOR, STAT3, Cyclin D1 and c-myc protein expression influence 1) GFP-ART1 group compared with un-transfection group. There was no significant difference in the expression of protein in group un-transfection and GFP-Vector (P0.05). (2) (2) in body experiment 1) the expression of ART1, P-AKT, m TOR and STAT3 expressed in the high NE state of type 2 diabetes mellitus mice. There was no significant difference between the two groups (P0.05).2) ART1 high expression of p-AKT, AKT, m TOR, and STAT3 protein expression in different NE mice of type 2 diabetes mellitus with the expression of Western blot: the non operative group (GFP-ART1 group), the sham operation group, the tumor body tissue, the tumor tissue, the protein expression of three groups had no significant difference. The expression of P-AKT, m TOR and STAT3 protein in group RT1 and LSO group was significantly higher than that in group LSD and GFP-ART1 group (P0.05). Conclusion: 1, the expression of ART1 in colorectal carcinoma with type 2 diabetes is obviously enhanced, and the expression intensity of the lymph node group is higher than that in the non metastatic group, and the intensity of.ART1 expression is not related to the sex, the degree of differentiation and the tumor site, but the age, sex, and tumor part are not related. Diabetes is still an independent factor in the expression intensity of ART1. It suggests that ART1 may play a role in the development of cancer in type 2 diabetes with colorectal cancer. It may play a role in the development of cancer in type 2 diabetic mice. The growth of the tumor is faster, the volume is greater, the weight is heavier, the survival time is shorter, and the ART1 is higher. At the time of expression, the above phenomenon is more obvious. Silence ART1 can inhibit the proliferation activity of NE induced colorectal CT26 cells, and the cells are mainly blocked at G1 stage. It suggests that ART1 has a promoting effect on the growth of colorectal carcinoma in type 2 diabetic mice, and ART1 can be regulated by AKT under the high NE state of diabetes, and then affects AKT/m TOR/STAT3 signaling pathway. Interfering with the downstream gene cyclin D1, c-myc expression and affecting the proliferation of colorectal cancer cells is expected to be a candidate target for the treatment of colorectal cancer with high NE levels in diabetes.
【學(xué)位授予單位】：重慶醫(yī)科大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2017
【分類號(hào)】：R735.34;R587.1

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 范國利;表皮生長因子受體在大腸癌中表達(dá)的意義[J];陜西醫(yī)學(xué)雜志;2000年01期

2 高梅澾,薛東波,趙明,李愛東,呂洪光,李泮泉,劉淑德;83例大腸癌多藥耐藥基因的檢測[J];中國現(xiàn)代醫(yī)學(xué)雜志;2001年12期

3 李俊,曹樺,吳寧,孟紅,汪永壽,陳玉祥,程雄;大腸癌術(shù)后復(fù)發(fā)與血管內(nèi)皮細(xì)胞生長因子及其受體表達(dá)的關(guān)系[J];華西醫(yī)學(xué);2002年04期

4 楊磊,丁彥青,張進(jìn)華;廣東地區(qū)2 037例大腸癌臨床病理分析[J];第一軍醫(yī)大學(xué)學(xué)報(bào);2003年11期

5 黃寧霞,胡建群;大腸癌637例臨床病理分析[J];九江醫(yī)學(xué);2003年01期

6 高梅澾,謝向臣,幺春艷,呂洪光;復(fù)發(fā)及多源發(fā)大腸癌多藥耐藥基因檢測[J];大腸肛門病外科雜志;2004年04期

7 張茂;德力格爾圖;;血管內(nèi)皮生長因子與大腸癌的研究進(jìn)展[J];內(nèi)蒙古醫(yī)學(xué)雜志;2007年09期

8 邵春紅;盧志明;;大腸癌[J];山東醫(yī)藥;2008年48期

9 費(fèi)伯健;吳露露;周士福;齊曉薇;;胰島素樣生長因子Ⅰ、胰島素樣生長因子Ⅰ受體在大腸癌中的表達(dá)及其意義[J];生物醫(yī)學(xué)工程與臨床;2009年06期

10 肖著軍;許岸高;;白細(xì)胞介素-8與大腸癌關(guān)系的研究進(jìn)展[J];廣東醫(yī)學(xué);2012年22期

相關(guān)會(huì)議論文 前10條

1 郭善禹;杜寬航;卜文;;細(xì)胞外基質(zhì)金屬蛋白酶誘導(dǎo)因子在大腸癌中的表達(dá)意義[A];2001'全國腫瘤外科學(xué)術(shù)會(huì)議論文匯編[C];2001年

2 鄭樹;;我國大腸癌易感人群研究[A];面向21世紀(jì)的科技進(jìn)步與社會(huì)經(jīng)濟(jì)發(fā)展（下冊(cè)）[C];1999年

3 肖冰;王媛媛;張亞歷;;大腸癌干細(xì)胞作用相關(guān)基因及信號(hào)通路的篩選鑒定[A];第二十三屆全國中西醫(yī)結(jié)合消化系統(tǒng)疾病學(xué)術(shù)會(huì)議暨消化疾病診治進(jìn)展學(xué)習(xí)班論文匯編[C];2011年

4 崔q輝;陳棟;楊振宇;;細(xì)胞粘附分子在大腸癌組織中表達(dá)及其臨床意義[A];第十一次全國中西醫(yī)結(jié)合大腸肛門病學(xué)術(shù)會(huì)議論文匯編[C];2006年

5 鄭樹;蔡心涵;曹江;耿禮義;鄭雷;張顏明;施正政;;人新的大腸癌負(fù)相關(guān)基因的研究[A];第六次全國大腸癌會(huì)議暨中日韓大腸癌會(huì)議論文匯編[C];1998年

6 耿敬姝;王艷穎;馮占軍;趙玉蘭;趙家宏;;大腸癌細(xì)胞增殖與P~(16)表達(dá)關(guān)系的研究[A];2000全國腫瘤學(xué)術(shù)大會(huì)論文集[C];2000年

7 雷雯;周錫庚;郁寶銘;陳曉耕;王清水;;血管內(nèi)皮生長因子和血管生成與大腸癌發(fā)展的關(guān)系[A];2001'全國腫瘤外科學(xué)術(shù)會(huì)議論文匯編[C];2001年

8 丁杰;;血管內(nèi)皮細(xì)胞生長因子與大腸癌治療[A];2007年貴州省醫(yī)學(xué)會(huì)外科分會(huì)學(xué)術(shù)年會(huì)論文匯編[C];2007年

9 申洪;;大腸癌組織結(jié)構(gòu)的體視學(xué)診斷參數(shù)研究[A];首屆粵港生物物理學(xué)術(shù)研討會(huì)論文集[C];1999年

10 許紅民;王強(qiáng);白雪娟;鐘定榮;曹秀堂;張金萍;丁彥青;姚開泰;;大腸癌差異表達(dá)基因的篩查[A];中華醫(yī)學(xué)會(huì)病理學(xué)分會(huì)2005年學(xué)術(shù)年會(huì)論文匯編[C];2005年

相關(guān)重要報(bào)紙文章 前7條

1 記者 施嘉奇;抽點(diǎn)血,找出大腸癌早期線索[N];文匯報(bào);2010年

2 記者 衣曉峰 靳萬慶 通訊員 李曉麗;大腸癌多藥耐藥判斷標(biāo)準(zhǔn)有新“尺度”[N];中國中醫(yī)藥報(bào);2003年

3 何苗苗 蔣卓勤;飲食相關(guān)成分在大腸癌發(fā)生中的作用[N];中國中醫(yī)藥報(bào);2003年

4 通訊員 方序 周煒 記者 宦建新;科學(xué)家發(fā)現(xiàn)大腸癌靶向細(xì)胞[N];科技日?qǐng)?bào);2014年

5 記者 張燦燦 特約記者 陸桂芳 通訊員 方序;加劇大腸癌進(jìn)展關(guān)鍵細(xì)胞現(xiàn)形[N];健康報(bào);2014年

6 記者 張樂;一種細(xì)胞會(huì)導(dǎo)致大腸癌腫瘤惡化[N];新華每日電訊;2014年

7 衣曉峰 李曉麗;腸癌多藥耐藥判斷有新說[N];健康報(bào);2003年

相關(guān)博士學(xué)位論文 前10條

1 劉陽;長鏈非編碼RNA DANCR在大腸癌中的表達(dá)及其功能研究[D];山東大學(xué);2016年

2 曹丹丹;基于二代測序技術(shù)的潰瘍性結(jié)腸炎相關(guān)性大腸癌變異譜分析[D];中國科學(xué)院北京基因組研究所;2015年

3 陳文雯;ART1對(duì)2型糖尿病高NE狀態(tài)大腸癌生長影響及機(jī)制研究[D];重慶醫(yī)科大學(xué);2017年

4 邱云平;基于色譜質(zhì)譜聯(lián)用技術(shù)的大腸癌代謝組學(xué)研究[D];上海交通大學(xué);2008年

5 馮曉瑩;胰島素樣生長因子系統(tǒng)在大腸癌的表達(dá)及意義研究[D];大連醫(yī)科大學(xué);2007年

6 馬怡茗;大腸癌發(fā)生發(fā)展及轉(zhuǎn)移相關(guān)分子的篩選和生物學(xué)功能研究[D];中國協(xié)和醫(yī)科大學(xué);2010年

7 陳遠(yuǎn)光;人大腸癌組織蛋白質(zhì)組二維凝膠電泳技術(shù)的建立及應(yīng)用[D];中南大學(xué);2003年

8 畢新宇;大腸癌病理學(xué)特征與預(yù)后的關(guān)系及硒蛋白-P在大腸癌組織中表達(dá)及其臨床意義[D];中國協(xié)和醫(yī)科大學(xué);2004年

9 王媛媛;大腸癌干細(xì)胞基因表達(dá)譜特點(diǎn)及其信號(hào)通路的篩選鑒定[D];南方醫(yī)科大學(xué);2011年

10 葉霖;單�；视椭久冈诖竽c癌中的作用及其作用機(jī)制的初步探討[D];華中科技大學(xué);2011年

相關(guān)碩士學(xué)位論文 前10條

1 唐光明;p53及其上游基因ATM、下游基因PUMA在大腸癌中的表達(dá)及意義[D];川北醫(yī)學(xué)院;2015年

2 王苗鋒;大腸癌組織中VEGF、MIF的表達(dá)及臨床意義[D];安徽醫(yī)科大學(xué);2015年

3 汝干;LncRNA-MALAT1與Hsa-miR-1互作機(jī)制對(duì)大腸癌放射敏感性的影響研究[D];蘇州大學(xué);2015年

4 王茜;細(xì)胞周期相關(guān)激酶在大腸癌組織中的表達(dá)及其意義[D];山東大學(xué);2015年

5 張明謙;ANKRD18B基因在肺癌和大腸癌中的甲基化與表達(dá)分析[D];第三軍醫(yī)大學(xué);2015年

6 趙碩;IDO在大腸癌組織中的表達(dá)及臨床意義[D];濱州醫(yī)學(xué)院;2014年

7 高麗萍;LEA、CDw75抗原在大腸癌中的表達(dá)及其臨床意義[D];昆明醫(yī)科大學(xué);2015年

8 肉克彥·庫達(dá)來提;維吾爾族與漢族大腸癌臨床病理特征及hMLH1、hMSH2蛋白表達(dá)差異[D];新疆醫(yī)科大學(xué);2015年

9 胡金龍;自噬相關(guān)基因在大腸癌中的表達(dá)及意義的相關(guān)性研究[D];濱州醫(yī)學(xué)院;2014年

10 李明;大腸癌中NRP2表達(dá)調(diào)控相關(guān)miRNA的預(yù)測及鑒定[D];濱州醫(yī)學(xué)院;2014年

，

本文編號(hào)：2146000